Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28789388 | 1.00 | CA2 (0.67) | CA2ALDH1A1L3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL13230 | 1.00 | CA2 (0.67) | CA2ALDH1A1L3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL3575904 | 0.95 | TDP1 (0.66) | CA2ALDH1A1L3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL3575901 | 0.95 | TDP1 (0.66) | CA2ALDH1A1L3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL5537767 | 0.93 | CA2 (0.75) | CA2ALDH1A1L3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL6787910 | 0.93 | CA2 (0.75) | CA2ALDH1A1L3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL1750558 | 0.91 | CA2 (0.64) | CA2ALDH1A1L3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL5036076 | 0.91 | CA2 (0.64) | CA2ALDH1A1L3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL6787220 | 0.90 | CA2 (0.59) | CA2 | |
| SCHEMBL6787214 | 0.90 | CA2 (0.59) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595398-B2 | N-(5-membered aromatic ring)-amido anti-viral compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | claimed |
| JP-9183764-A | — | — | None | — | — | JP | disclosed |
| WO-2026103853-A1 | TSHR ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF | 长春金赛药业有限责任公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026103887-A1 | PROLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 北京康辰药业股份有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098667-A1 | USP30 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | 长春金赛药业有限责任公司 | 2026-05-15 | — | — | WO | disclosed |
| CN-122036731-A | CB1 receptor inverse agonist compound, pharmaceutical composition, preparation method and application thereof | 北京康辰药业股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12617770-B2 | IRAK inhibitor and preparation method therefor and use thereof | WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4722211-A1 | FGFR2/3 SELECTIVE INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-5332735-A | Antiamnesic activity | ADIR ET COMPAGNIE (FR) | 1994-07-26 | — | — | US | disclosed |
| US-5332735-A | Antiamnesic activity | ADIR ET COMPAGNIE (FR) | 1994-07-26 | — | — | US | disclosed |
| EP-0486386-A2 | Novel derivatives of N-benzoylproline, process for their preparation and drugs containing them | ADIR ET COMPAGNIE (FR) | 1992-05-20 | — | — | EP | disclosed |
| EP-0486386-A2 | Novel derivatives of N-benzoylproline, process for their preparation and drugs containing them | ADIR ET COMPAGNIE (FR) | 1992-05-20 | — | — | EP | disclosed |
| US-4745124-A | THIO/ESTER PEPTIDES | UNIVERSITY OF MIAMI (US) | 1988-05-17 | — | — | US | disclosed |
| US-4494547-A | 2H-isoindolediones, their synthesis and use as radiosensitizers | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | disclosed |
| EP-0036713-A2 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-30 | — | — | EP | disclosed |
| US-4251628-A | HYDROLYSIS OF OLIGOPEPTIDES FOR RADIOISOTOPE ASSAY | VENTREX LABORATORIES, INC. | 1981-02-17 | — | — | US | disclosed |
| US-4115374-A | IODO-P-HYDROXYPHENYL-GLYCYLGLYCINE | RYAN JAMES WALTER | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617770-B2 | IRAK inhibitor and preparation method therefor and use thereof | IRAK1, IRAK2, IRAK3 | CA2 3450/4885ALDH1A1 1944/4885L3MBTL1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.